SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Öhrfelt Annika) "

Sökning: WFRF:(Öhrfelt Annika)

  • Resultat 1-10 av 40
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Bhattacharjee, Payel, 1984, et al. (författare)
  • Mass Spectrometric Analysis of Lewy Body-Enriched alpha-Synuclein in Parkinson's Disease
  • 2019
  • Ingår i: Journal of Proteome Research. - : American Chemical Society (ACS). - 1535-3893 .- 1535-3907. ; 18:5, s. 2109-2120
  • Tidskriftsartikel (refereegranskat)abstract
    • Parkinson's disease (PD) is characterized by intraneuronal inclusions of aggregated alpha-synuclein protein (so-called Lewy bodies) in distinct brain regions. Multiple posttranslational modifications may affect the structure and function of alpha-synuclein. Mass spectrometry-based analysis may be useful for the characterization and quantitation of alpha-synuclein forms, but has proven challenging, mainly due to the insolubility of Lewy bodies in aqueous buffer. In the present study, we developed a novel method by combining differential solubilization with immunoprecipitation and targeted proteomics using liquid chromatography and tandem mass spectrometry. Brain tissue homogenization and sample preparation were modified to facilitate analysis of soluble, detergent-soluble, and detergent-insoluble protein fractions (Lewy body-enriched). The method was used to compare alpha-synuclein forms from cingulate cortex (affected) and occipital cortex (unaffected) in two study sets of PD patients and controls. We identified similar to 20 modified alpha-synuclein variants, including species with N-terminal acetylation and C-terminal truncations at amino acids 103 and 119. The levels of alpha-synuclein forms Ac-alpha-syn(1-6), alpha-syn(13-21), alpha-syn(35-43), alpha-syn(46-58), alpha-syn(61-80), and alpha-syn(81-96) except alpha-syn(103-119) were significantly increased in PD cingulate region compared to controls in the Lewy body-enriched alpha-synuclein fraction. In the soluble fraction, only Ac-alpha-syn(1-6) was significantly increased in PD compared to controls. None of the detected alpha-synuclein variants were Lewy body-specific, but acetylated forms should be examined further as potential biomarkers for abnormal alpha-synuclein accumulation.
  •  
2.
  • Brinkmalm, Ann, et al. (författare)
  • Detection of α-Synuclein in Biological Samples Using Mass Spectrometry
  • 2019
  • Ingår i: Methods in molecular biology (Clifton, N.J.). - New York, NY : Springer. - 1940-6029. ; , s. 209-220
  • Bokkapitel (refereegranskat)abstract
    • Here we describe a method using mass spectrometry to characterize and quantify immuno-enriched α-synuclein forms from biochemically fractionated brain tissue.
  •  
3.
  • Brinkmalm, Gunnar, et al. (författare)
  • An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid β and amyloid precursor protein in human and cat cerebrospinal fluid.
  • 2012
  • Ingår i: Journal of mass spectrometry : JMS. - : Wiley. - 1096-9888 .- 1076-5174. ; 47:5, s. 591-603
  • Tidskriftsartikel (refereegranskat)abstract
    • Amyloid precursor protein (APP) is the precursor protein to amyloid β (Aβ), the main constituent of senile plaques in Alzheimer's disease (AD). Endogenous Aβ peptides reflect the APP processing, and greater knowledge of different APP degradation pathways is important to understand the mechanism underlying AD pathology. When one analyzes longer Aβ peptides by low-energy collision-induced dissociation tandem mass spectrometry (MS/MS), mainly long b-fragments are observed, limiting the possibility to determine variations such as amino acid variants or post-translational modifications (PTMs) within the N-terminal half of the peptide. However, by using electron capture dissociation (ECD), we obtained a more comprehensive sequence coverage for several APP/Aβ peptide species, thus enabling a deeper characterization of possible variants and PTMs. Abnormal APP/Aβ processing has also been described in the lysosomal storage disease Niemann-Pick type C and the major large animal used for studying this disease is cat. By ECD MS/MS, a substitution of Asp7 → Glu in cat Aβ was identified. Further, sialylated core 1 like O-glycans at Tyr10, recently discovered in human Aβ (a previously unknown glycosylation type), were identified also in cat cerebrospinal fluid (CSF). It is therefore likely that this unusual type of glycosylation is common for (at least) species belonging to the magnorder Boreoeutheria. We here describe a detailed characterization of endogenous APP/Aβ peptide species in CSF by using an online top-down MS-based method.
  •  
4.
  • Brinkmalm, Gunnar, et al. (författare)
  • Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease.
  • 2013
  • Ingår i: Brain research. - : Elsevier BV. - 1872-6240 .- 0006-8993. ; 1513, s. 117-26
  • Tidskriftsartikel (refereegranskat)abstract
    • Cerebral accumulation of amyloid β (Aβ) is a pathological hallmark of Alzheimer's disease (AD). Proteolytic processing of amyloid precursor protein (APP) by α- or β-secretase results in two soluble metabolites, sAPPα and sAPPβ, respectively. However, previous data have shown that both α- and β-secretase have multiple cleavage sites. The aim of this study was to characterize the C-termini of sAPPα and sAPPβ in cerebrospinal fluid (CSF) by mass spectrometry (MS) and to evaluate whether different combinations of these fragments better separate between AD patients and controls by comparing two different sAPP immunoassays. Methods: Using immunoprecipitation and high resolution MS, the APP species present in CSF were investigated. CSF levels of sAPPα and sAPPβ from patients with AD (n=43) and from non-demented controls (n=44) were measured using AlphaLISA and MSD immunoassays that employ different antibodies for C-terminal recognition of sAPPα. Results: Four different C-terminal forms of sAPP were identified, sAPPβ-M671, sAPPβ-Y681, sAPPα-Q686, and sAPPα-K687 (APP770 numbering). Neither immunoassay for the sAPP species could separate the two patient groups. The correlation (R(2)) between the two immunoassays was 0.41 for sAPPα and 0.45 for sAPPβ. Conclusion: Using high resolution MS, we show here for the first time that sAPPα in CSF ends at Q686 and K687. The findings also support the conclusion from several previous studies that sAPPα and sAPPβ levels are unaltered in AD.
  •  
5.
  • Brinkmalm-Westman, Ann, 1966, et al. (författare)
  • Explorative and targeted neuroproteomics in Alzheimer's disease.
  • 2015
  • Ingår i: Biochimica et biophysica acta. - : Elsevier BV. - 0006-3002. ; 1854:7
  • Tidskriftsartikel (refereegranskat)abstract
    • Alzheimer's disease (AD) is a progressive brain amyloidosis that injures brain regions involved in memory consolidation and other higher brain functions. Neuropathologically, the disease is characterized by accumulation of a 42 amino acid peptide called amyloid β (Aβ42) in extracellular senile plaques, intraneuronal inclusions of hyperphosphorylated tau protein in neurofibrillary tangles, and neuronal and axonal degeneration and loss. Biomarker assays capturing these pathologies have been developed for use on cerebrospinal fluid samples but there are additional molecular pathways that most likely contribute to the neurodegeneration and full clinical expression of AD. One way of learning more about AD pathogenesis is to identify novel biomarkers for these pathways and examine them in longitudinal studies of patients in different stages of the disease. Here, we discuss targeted proteomic approaches to study AD and AD-related pathologies in closer detail and explorative approaches to discover novel pathways that may contribute to the disease. This article is part of a Special Issue entitled: Neuroproteomics: Applications in neuroscience and neurology.
  •  
6.
  • Brinkmalm-Westman, Ann, 1966, et al. (författare)
  • SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease
  • 2014
  • Ingår i: Molecular Neurodegeneration. - : Springer Science and Business Media LLC. - 1750-1326. ; 9
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Synaptic degeneration is an early pathogenic event in Alzheimer's disease, associated with cognitive impairment and disease progression. Cerebrospinal fluid biomarkers reflecting synaptic integrity would be highly valuable tools to monitor synaptic degeneration directly in patients. We previously showed that synaptic proteins such as synaptotagmin and synaptosomal-associated protein 25 (SNAP-25) could be detected in pooled samples of cerebrospinal fluid, however these assays were not sensitive enough for individual samples. Results: We report a new strategy to study synaptic pathology by using affinity purification and mass spectrometry to measure the levels of the presynaptic protein SNAP-25 in cerebrospinal fluid. By applying this novel affinity mass spectrometry strategy on three separate cohorts of patients, the value of SNAP-25 as a cerebrospinal fluid biomarker for synaptic integrity in Alzheimer's disease was assessed for the first time. We found significantly higher levels of cerebrospinal fluid SNAP-25 fragments in Alzheimer's disease, even in the very early stages, in three separate cohorts. Cerebrospinal fluid SNAP-25 differentiated Alzheimer's disease from controls with area under the curve of 0.901 (P < 0.0001). Conclusions: We developed a sensitive method to analyze SNAP-25 levels in individual CSF samples that to our knowledge was not possible previously. Our results support the notion that synaptic biomarkers may be important tools for early diagnosis, assessment of disease progression, and to monitor drug effects in treatment trials.
  •  
7.
  • Brinkmalm-Westman, Ann, 1966, et al. (författare)
  • Targeting synaptic pathology with a novel affinity mass spectrometry approach.
  • 2014
  • Ingår i: Molecular & cellular proteomics : MCP. - 1535-9484. ; 13:10, s. 2584-92
  • Tidskriftsartikel (refereegranskat)abstract
    • We report a novel strategy for studying synaptic pathology by concurrently measuring levels of four SNARE complex proteins from individual brain tissue samples. This method combines affinity purification and mass spectrometry and can be applied directly for studies of SNARE complex proteins in multiple species or modified to target other key elements in neuronal function. We use the technique to demonstrate altered levels of presynaptic proteins in Alzheimer disease patients and prion-infected mice.
  •  
8.
  • Bäckström, David C, et al. (författare)
  • Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease
  • 2015
  • Ingår i: JAMA Neurology. - : American Medical Association. - 2168-6149 .- 2168-6157. ; 72:10, s. 1175-1182
  • Tidskriftsartikel (refereegranskat)abstract
    • IMPORTANCE: Alterations in cerebrospinal fluid (CSF) have been found in Parkinson disease (PD) and in PD dementia (PDD), but the prognostic importance of such changes is not well known. In vivo biomarkers for disease processes in PD are important for future development of disease-modifying therapies. OBJECTIVE: To assess the diagnostic and prognostic value of a panel of CSF biomarkers in patients with early PD and related disorders. DESIGN, SETTING, AND PARTICIPANTS: Regional population-based, prospective cohort study of idiopathic parkinsonism that included patients diagnosed between January 1, 2004, and April 30, 2009, by amovement disorder team at a university hospital that represented the only neurology clinic in the region. Participants were 128 nondemented patients with new-onset parkinsonism (104 with PD, 11 with multiple system atrophy, and 13 with progressive supranuclear palsy) who were followed up for 5 to 9 years. At baseline, CSF from 30 healthy control participants was obtained for comparison. MAIN OUTCOMES AND MEASURES: Cerebrospinal fluid concentrations of neurofilament light chain protein, Aβ1-42, total tau, phosphorylated tau, α-synuclein, and heart fatty acid-binding protein were quantified by 2 blinded measurements (at baseline and after 1 year). Follow-up included an extensive neuropsychological assessment. As PD outcome variables, mild cognitive impairment and incident PDD were diagnosed based on published criteria. RESULTS: Among the 128 study participants, the 104 patients with early PD had a different CSF pattern compared with the 13 patients with progressive supranuclear palsy (baseline area under the receiver operating characteristic curve, 0.87; P < .0001) and the 30 control participants (baseline area under the receiver operating characteristic curve, 0.69; P = .0021). A CSF biomarker pattern associated with the development of PDD was observed. In PD, high neurofilament light chain protein, low Aβ1-42, and high heart fatty acid-binding protein at baseline were related to future PDD as analyzed by Cox proportional hazards regression models. Combined, these early biomarkers predicted PDD with high accuracy (hazard ratio, 11.8; 95% CI, 3.3-42.1; P = .0001) after adjusting for possible confounders. CONCLUSIONS AND RELEVANCE: The analyzed CSF biomarkers have potential usefulness as a diagnostic tool in patients with parkinsonism. In PD, high neurofilament light chain protein, low Aβ1-42, and high heart fatty acid-binding protein were related to future PDD, providing new insights into the etiology of PDD.
  •  
9.
  • Førland, Marthe Gurine, et al. (författare)
  • Evolution of cerebrospinal fluid total α-synuclein in Parkinson's disease.
  • 2018
  • Ingår i: Parkinsonism & related disorders. - : Elsevier BV. - 1873-5126 .- 1353-8020. ; 49, s. 4-8
  • Tidskriftsartikel (refereegranskat)abstract
    • Cerebrospinal fluid (CSF) total α-synuclein is considered a potential biomarker for Parkinson's disease (PD), but little is known about the evolution of this marker during the course of the disease. Our objective was to investigate whether CSF total α-synuclein concentrations change over time and are associated with motor and cognitive function in PD.CSF total α-synuclein concentrations were quantified in 56 longitudinally followed PD patients, 27 of whom provided CSF repeatedly 2 and/or 4 years later. Another 18 subjects were included as controls. The samples were analyzed using two independent, validated ELISA methods: our recently developed and validated in-house ELISA and a commercial kit from BioLegend.CSF total α-synuclein levels did not distinguish PD patients from controls, displayed no substantial changes during a period of up to 4 years, and did not predict subsequent motor or cognitive decline. These findings were consistent for both analytical methods.Our findings do not support the clinical utility of total α-synuclein as a single diagnostic or prognostic biomarker in PD.
  •  
10.
  • Førland, Marthe Gurine, et al. (författare)
  • Validation of a new assay for α-synuclein detection in cerebrospinal fluid.
  • 2017
  • Ingår i: Clinical chemistry and laboratory medicine. - : Walter de Gruyter GmbH. - 1437-4331 .- 1434-6621. ; 55:2
  • Tidskriftsartikel (refereegranskat)abstract
    • Abnormal α-synuclein aggregation and deposition is the pathological hallmark of Parkinson's disease (PD) and dementia with Lewy bodies (DLB), but is also found in Alzheimer disease (AD). Therefore, there is a gaining interest in α-synuclein in cerebrospinal fluid (CSF) as potential biomarker for these neurodegenerative diseases. To broaden the available choices of α-synuclein measurement in CSF, we developed and validated a new assay for detecting total α-synuclein.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 40
Typ av publikation
tidskriftsartikel (38)
forskningsöversikt (1)
bokkapitel (1)
Typ av innehåll
refereegranskat (40)
Författare/redaktör
Blennow, Kaj, 1958 (35)
Zetterberg, Henrik, ... (34)
Öhrfelt, Annika, 197 ... (27)
Öhrfelt Olsson, Anni ... (13)
Brinkmalm, Gunnar (12)
Hansson, Oskar (11)
visa fler...
Brinkmalm-Westman, A ... (10)
Wallin, Anders, 1950 (8)
Andreasson, Ulf, 196 ... (8)
Minthon, Lennart (6)
Portelius, Erik, 197 ... (6)
Brinkmalm, Ann (5)
Bjerke, Maria, 1977 (5)
Svensson, Johan, 196 ... (4)
Vanmechelen, Eugeen (4)
Hall, Sara (4)
Londos, Elisabet (3)
Kvartsberg, Hlin, 19 ... (3)
Andreasen, Niels (3)
Nägga, Katarina (3)
Sjödin, Simon (3)
Persson, Rita, 1951 (3)
Surova, Yulia (3)
Rolstad, Sindre, 197 ... (2)
Olsson, Bob, 1969 (2)
Forsgren, Lars (2)
Linder, Jan (2)
Heslegrave, Amanda (2)
Ashton, Nicholas J. (2)
Gobom, Johan (2)
Johansson, Per, 1966 (2)
Alves, Guido (2)
Lange, Johannes (2)
Tysnes, Ole-Bjørn (2)
Eckerström, Marie, 1 ... (2)
Nordlund, Arto, 1962 (2)
Bhattacharjee, Payel ... (2)
Edman, Åke (2)
Jonsson, Michael, 19 ... (2)
Eckerström, Carl (2)
Dumurgier, J. (2)
Paquet, C. (2)
Nutu, Magdalena, 196 ... (2)
Honer, William G. (2)
Olsson, Erik, 1960 (2)
Trupp, Miles (2)
Hugon, J (2)
Bouaziz-Amar, E. (2)
Göthlin, Mattias, 19 ... (2)
Førland, Marthe Guri ... (2)
visa färre...
Lärosäte
Göteborgs universitet (39)
Lunds universitet (8)
Karolinska Institutet (3)
Umeå universitet (2)
Linköpings universitet (2)
Örebro universitet (1)
visa fler...
Sveriges Lantbruksuniversitet (1)
visa färre...
Språk
Engelska (40)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (40)
Naturvetenskap (1)
Teknik (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy